PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v9i5.12159ArticleCurrent Status and Prospects of Diagnosis and Intervention for HR-HPV Persistent Infectionhttps://artdesignp.com/journal/PAR/9/5/10.26689/par.v9i5.12159TanPing,XiaoYanbing2025952025-10-13Persistent infection with high-risk human papillomavirus (HR-HPV) is the core pathogenic factor of cervical cancer (CC). Although HPV vaccination is an effective primary prevention method for CC, the global vaccination rate is generally insufficient (target population vaccination rate in China < 5%), far from meeting the requirements for herd immunity (80%) and the WHO target (90%). However, only about 10% of HR-HPV infections progress to persistent infections. Therefore, identifying and intervening in the “HR-HPV persistent infection” population can systematically narrow the scope of prevention and control, reduce prevention and control costs, and provide a new path for low-income countries to explore suitable prevention and control models for CC. Based on this understanding, the team has pioneered a systematic method for identifying HR-HPV persistent infections and a tiered intervention system based on drug classification, which has achieved good results in both basic research and clinical observations. This article will summarize the current research status of “HR-HPV persistent infection” in relation to CIN and CC, as well as the team’s relevant concepts and research results, to provide a reference for the identification and intervention of “HR-HPV persistent infection.”

Han S, Lin M, Liu M, et al., 2025, Prevalence, Trends, and Geographic Distribution of Human Papillomavirus Infection in Chinese Women: A Summative Analysis of 2,728,321 Cases. BMC Medicine, 23: 158.

Bruno M, Panella M, Valenti G, et al., 2024, Vaginal Intraepithelial Neoplasia (VaIN) after Hysterectomy Is Strongly Associated with Persistent HR-HPV Infection. Cancers (Basel), 16(14): 2524.

Gardella B, Pasquali M, Dominoni M, 2022, Human Papillomavirus Cervical Infection: Many Ways to a Single Destination. Vaccines (Basel), 11(1): 22.

Kiamba E, Goodier M, Clarke E, 2025, Immune Responses to Human Papillomavirus Infection and Vaccination. Frontiers in Immunology, 16: 1591297.

Cai X, Xu L, 2024, Human Papillomavirus-Related Cancer Vaccine Strategies. Vaccines (Basel), 12(11): 1291.

Hang L, Dong B, Yuan X, 2024, Expression of ALDH1 Plays the Important Role during Generation and Progression in Human Cervical Cancer. Biotechnology and Genetic Engineering Reviews, 40(4): 3768–3779.

Zhang Z, Ma Q, Zhang L, et al., 2024, Human Papillomavirus and Cervical Cancer in the Microbial World: Exploring the Vaginal Microecology. Frontiers in Cellular and Infection Microbiology, 14: 1325500.

Ghanaat M, Goradel N, Arashkia A, et al., 2021, Virus against Virus: Strategies for Using Adenovirus Vectors in the Treatment of HPV-Induced Cervical Cancer. Acta Pharmacologica Sinica, 42(12): 1981–1990.

Fobian S, Mei X, Crezee J, et al., 2024, Increased Human Papillomavirus Viral Load Is Correlated to Higher Severity of Cervical Disease and Poorer Clinical Outcome: A Systematic Review. Journal of Medical Virology, 96(6): e29741.

Luo L, Cong Q, 2025, Screening Methods and Selection for Cervical Cancer. Journal of Practical Obstetrics and Gynecology, 41(07): 529–532.

Liu Y, 2023, High-Risk Human Papillomavirus Testing Is an Effective Method for Cervical Cancer Screening – An Interview with Xiao Yanbing, Director of Obstetrics and Gynecology at Maternity and Child Healthcare Hospital in Zunyi, Guizhou Province. Women and Children’s Health Guide, 2(19): 4–6.

Wang P, Xiao Y, 2022, Advances in Research on Human Papillomavirus Infection and Treatment. Journal of Regional Anatomy and Operative Surgery, 31(12): 1107–1111.

Dong P, 2024, Screening of Human-Derived Antimicrobial Lactic Acid Bacteria and Study on Their Antimicrobial Mechanism. thesis, Henan University of Technology.

Cui M, Wu Y, Liu Z, et al., 2025, Advances in the Interrelated Nature of Vaginal Microecology, HPV Infection, and Cervical Lesions. Frontiers in Cellular and Infection Microbiology, 15: 1608195.

Wang P, 2023, The Effect of Lactic Acid Bacteria Combined with Meifukang on HPV18 E6/E7 Gene Expression and Cell Activity in Hela Cells. thesis, Zunyi Medical University.

Lu W, Xiao Y, 2024, Experimental Study on the Effect of Lactic Acid Bacteria Fermentation Broth Combined with Ruxian Ta on the Activity of HeLa Cells and HPV18 Viral Load. Chinese Journal of Microecology, 36(02): 147–153.

Zhang N, 2023, Experimental Study on the Effect of Lactic Acid Bacteria Fermentation Broth Combined with Ribavirin on HPV18 E6/E7 Gene Expression and Cell Inhibition in Hela Cells. thesis, Zunyi Medical University.

Fu X, Zhou W, Lu Y, 2025, Implementation Strategies for Global Human Papillomavirus Vaccine Immunization: Implications for China. Chinese Journal of Viral Diseases, 15(02): 151–157.

Li M, Wei L, Sui L, et al., 2023, Guidelines for Cervical Cancer Screening in China (Part 1). Electronic Journal of Comprehensive Cancer Treatment, 9(03): 41–48.